Synonym
Moxonidine hydrochloride; Moxonidine HCl
IUPAC/Chemical Name
4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine hydrochloride
InChi Key
ZZPAWQYZQVUVHX-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H12ClN5O.ClH/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9;/h3-4H2,1-2H3,(H2,11,12,15);1H
SMILES Code
Cl.COc1nc(C)nc(Cl)c1NC2=NCCN2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
278.14
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kawada T, Shimizu S, Yamamoto H, Miyamoto T, Shishido T, Sugimachi M. Peripheral versus central effect of intravenous moxonidine on rat carotid sinus baroreflex-mediated sympathetic arterial pressure regulation. Life Sci. 2017 Dec 1;190:103-109. doi: 10.1016/j.lfs.2017.09.038. Epub 2017 Sep 28. PubMed PMID: 28964815.
2: Fouda MA, El-Sayed SS, Abdel-Rahman AA. Restoration of rostral ventrolateral medulla cystathionine-γ lyase activity underlies moxonidine-evoked neuroprotection and sympathoinhibition in diabetic rats. J Pharmacol Exp Ther. 2017 Nov 13. pii: jpet.117.243865. doi: 10.1124/jpet.117.243865. [Epub ahead of print] PubMed PMID: 29133386.
3: Lambert EA, Sari CI, Eikelis N, Phillips SE, Grima M, Straznicky NE, Dixon JB, Esler M, Schlaich MP, Head GA, Lambert GW. Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity (Silver Spring). 2017 Nov;25(11):1894-1902. doi: 10.1002/oby.21962. Epub 2017 Sep 2. PubMed PMID: 28865109.
4: Rubio-Beltrán E, Labastida-Ramírez A, Hernández-Abreu O, MaassenVanDenBrink A, Villalón CM. Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol. 2017 Oct 5;812:97-103. doi: 10.1016/j.ejphar.2017.07.020. Epub 2017 Jul 8. PubMed PMID: 28694067.
5: Zhang W, Li X, Liu Y, Chen H, Gong J. Activation of imidazoline I(1) receptor by moxonidine regulates the progression of liver fibrosis in the Nrf2-dependent pathway. Biomed Pharmacother. 2017 Jun;90:821-834. doi: 10.1016/j.biopha.2017.04.025. Epub 2017 Apr 20. PubMed PMID: 28437886.
